卡博特(CBT)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CBT 卡博特

交易中 04-08 13:22:16 EDT

76.27

+1.42

+1.90%

最高76.78	最低75.35	成交量9.01万
今开76.76	昨收74.85	日振幅1.91%
总市值39.83亿	流通市值39.83亿	总股本5,222万
成交额683.78万	换手率0.17%	流通股本5,222万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"CBT","market":"US","secType":"STK","nameCN":"卡博特","latestPrice":76.27,"timestamp":1775668930924,"preClose":74.85,"halted":0,"volume":90059,"delay":0,"changeRate":0.018971275885103566,"floatShares":52221600,"shares":52221600,"eps":5.717876,"marketStatus":"交易中","change":1.42,"latestTime":"04-08 13:22:16 EDT","open":76.76,"high":76.778,"low":75.35,"amount":6837798.019839999,"amplitude":0.019078,"askPrice":76.31,"askSize":16,"bidPrice":76.15,"bidSize":100,"shortable":3,"etf":0,"ttmEps":5.717876,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1775678400000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":74.85,"dividendRate":0.023338,"postHourTrading":{"tag":"盘后","latestPrice":74.85,"preClose":74.85,"latestTime":"19:13 EDT","volume":9169,"amount":686377.22,"timestamp":1775603589448,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.401302,"impliedVol":0.3281,"impliedVolPercentile":0.556},"requestUrl":"/m/hq/s/CBT","defaultTab":"news","newsList":[{"id":"2620420690","title":"港股异动 | 拨康视云-B(02592)跌超6%创新低 宣布撤回CBT-009新药临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2620420690","media":"智通财经","labels":["executive","productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620420690?lang=zh_cn&edition=full","pubTime":"2026-03-20 10:35","pubTimestamp":1773974109,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，拨康视云-B跌超6%，低见1.82港元刷新上市以来新低。在提交新药临床试验申请后，药审中心批准了一款可比药品在中国上市。经后续与药审中心沟通后，公司相信由于各区域监管要求不同，将中国纳入多地区临床试验可能存在困难。为避免后续研发风险，及更好地分配集团的资源，公司已决定主动就可能于中国进行的第三期试验撤回现有的新药临床试验申请。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416373.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"executive,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK4585","VXUS","02592","BK4090","BK1161","CBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620244220","title":"拨康视云-B(02592)：撤回CBT-009新药临床试验申请 重新评估临床开发策略","url":"https://stock-news.laohu8.com/highlight/detail?id=2620244220","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620244220?lang=zh_cn&edition=full","pubTime":"2026-03-19 19:05","pubTimestamp":1773918320,"startTime":"0","endTime":"0","summary":"在提交新药临床试验申请后，药审中心批准了一款可比药品在中国上市。经后续与药审中心沟通后，公司相信由于各区域监管要求不同，将中国纳入多地区临床试验可能存在困难。为避免后续研发风险，及更好地分配集团的资源，公司已决定主动就可能于中国进行的第三期试验撤回现有的新药临床试验申请。待完成相关补充研究或调整临床试验方案后，公司将根据情况再次与药审中心进行临床试验申请前咨询会议或重新提交临床试验申请。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416056.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4090","BK1161","CBT","02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611615103","title":"拨康视云-B(02592)：CBT-199新药临床试验申请已生效，临床试验被认定为可安全推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2611615103","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611615103?lang=zh_cn&edition=full","pubTime":"2026-02-16 12:45","pubTimestamp":1771217106,"startTime":"0","endTime":"0","summary":"由于美国药管局未发出任何临床试验暂停令，新药临床试验申请现已生效，临床试验被认定为可安全推进。CBT-199已自2023年6月起于临床前动物研究中进行安全性和耐受性评估，有关研究预期将有助于未来的临床试验。本公司认为，由于CBT-199的临床试验现被认为可安全推进，标志着CBT-199临床开发的关键里程碑，且本集团已正式获授权启动第2阶段临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1405684.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02592","CBT","BK4090"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157866407","title":"卡博特公司董事会宣布派发季度股息","url":"https://stock-news.laohu8.com/highlight/detail?id=1157866407","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157866407?lang=zh_cn&edition=full","pubTime":"2026-02-03 05:34","pubTimestamp":1770068084,"startTime":"0","endTime":"0","summary":"2026年2月2日，波士顿——卡博特公司董事会于2026年1月9日（星期五）宣布，将向公司所有流通在外的普通股派发每股0.45美元的季度股息。此次股息将于2026年3月13日支付给在2026年2月27日营业时间结束时登记在册的股东。卡博特公司是一家全球性的特种化学品和高性能材料企业，总部位于马萨诸塞州波士顿。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CBT","BK4090"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183799657","title":"卡博特公司完成从普利司通收购墨西哥碳素制造公司","url":"https://stock-news.laohu8.com/highlight/detail?id=1183799657","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183799657?lang=zh_cn&edition=full","pubTime":"2026-02-02 22:01","pubTimestamp":1770040897,"startTime":"0","endTime":"0","summary":"卡博特公司（CBT）已正式完成对墨西哥碳素制造公司（Mexico Carbon Manufacturing S.a. De C.v.）的收购，该资产此前隶属于普利司通公司。此项交易的达成，标志着卡博特在全球碳素材料市场的战略布局进一步深化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4090","CBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176912660","title":"财报前瞻 ｜卡博特本季度营收预计降至8.87亿美元，看多观点占优","url":"https://stock-news.laohu8.com/highlight/detail?id=1176912660","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176912660?lang=zh_cn&edition=full","pubTime":"2026-01-27 10:45","pubTimestamp":1769481959,"startTime":"0","endTime":"0","summary":"卡博特将于2026年02月03日发布最新季度财报，市场关注营收与盈利同比下行的幅度以及核心业务的结构性改善迹象。市场一致预期显示，本季度卡博特营收预计为8.87亿美元，同比下降11.03%；调整后每股收益预计为1.41美元，同比下降18.89%；息税前利润预计为1.32亿美元，同比下降17.15%。基于近期机构对卡博特最新季度的观点，偏积极的看多意见占比较高。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻 ｜卡博特本季度营收预计降至8.87亿美元，看多观点占优","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166643810","title":"卡博特公司与大众集团电池制造子公司Powerco Se签署多年供应协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1166643810","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166643810?lang=zh_cn&edition=full","pubTime":"2026-01-07 22:00","pubTimestamp":1767794414,"startTime":"0","endTime":"0","summary":"卡博特公司（CBT）已正式与大众汽车集团旗下的电池制造业务单元——Powerco Se公司，达成一项为期数年的关键供应合作。\n此项协议标志着卡博特在电池材料供应链领域的重要布局，同时也为Powerco Se未来的电池生产提供了稳定的材料保障。双方的合作将进一步深化在电动汽车产业链中的协同效应。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4090","CBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601700867","title":"拨康视云-B(02592)成功向药品审评中心提交CBT-009新药临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2601700867","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601700867?lang=zh_cn&edition=full","pubTime":"2026-01-06 16:41","pubTimestamp":1767688918,"startTime":"0","endTime":"0","summary":"CBT-009是一种由本集团独立开发的新型、非水性阿托品眼用制剂，用于治疗5至19岁儿童及青少年的青少年近视。与现有水性阿托品滴眼液相比，CBT-009显著提升制剂稳定性，可在室温下长期储存且无需添加防腐剂，大幅改善患者用药依从性与使用体验。本公司认为，成功向药审中心提交新药临床试验申请，标志着CBT-009在中国临床开发的重要里程碑，为集团在该重要市场推进第三期临床试验奠定坚实基础。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1389297.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02592","BK4090","CBT","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2591198671","title":"港股异动 | 拨康视云-B(02592)一度跌近15% CBT-199眼科候选药物在美递交新药临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2591198671","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591198671?lang=zh_cn&edition=full","pubTime":"2025-12-16 10:20","pubTimestamp":1765851607,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，拨康视云-B一度跌近15%，12月5日至今回撤逾四成。截至发稿，跌11.59%，报4.96港元，成交额677.98万港元。消息面上，拨康视发布公告称，12月15日，公司全资附属公司ADS Therapeutics LLC向美国食品及药物管理局提交有关CBT-199的新药临床试验申请。CBT-199已自2023年6月起于临床前动物研究中进行安全性和耐受性评估，有关研究预期将有助于未来的临床试验。另值得注意的是，1月3日，拨康视云两位基石投资者将迎来限售股解禁。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381949.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4090","02592","CBT","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2591614559","title":"拨康视云-B(02592)向美国药管局提交有关CBT-199的新药临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2591614559","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591614559?lang=zh_cn&edition=full","pubTime":"2025-12-15 17:15","pubTimestamp":1765790138,"startTime":"0","endTime":"0","summary":"智通财经APP讯，拨康视云-B 发布公告，于2025年12月15日，本公司全资附属公司ADS Therapeutics LLC向美国食品及药物管理局提交有关CBT-199的新药临床试验申请。诚如本公司日期为2025年6月24日的招股章程所披露，本集团已于2023年在中国开始 CBT-199的药物发现过程。CBT-199已自2023年6月起于临床前动物研究中进行安全性和耐受性评估，有关研究预期将有助于未来的临床试验。提交新药临床试验申请为美国药管局启动药物审查程序以及取得监管批准以展开CBT-199的临床试验的第一步。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381573.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02592","BK1161","CBT","BK4090"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2590571809","title":"拨康视云-B(02592)成功举行CBT-004的第2期临床试验后会议","url":"https://stock-news.laohu8.com/highlight/detail?id=2590571809","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590571809?lang=zh_cn&edition=full","pubTime":"2025-12-12 16:36","pubTimestamp":1765528591,"startTime":"0","endTime":"0","summary":"第2期临床试验后会议乃基于2025年5月完成的第2期临床试验结果及2025年7月完成的临床试验报告而举行，该报告显示CBT-004在受试者中具有安全性且耐受性良好，并达到主要疗效终点及若干次要疗效终点。公司认为，成功举行第2期临床试验后会议标志着CBT-004临床开发取得重大进展，尤其是推动其进入第3期临床研究，为CBT-004新药申请及获批后的商业化铺平道路。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380876.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4090","BK1161","02592","CBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2590377514","title":"港股异动 | 拨康视云-B(02592)现涨超4% 附属将与美国FDA讨论CBT-004研发事项","url":"https://stock-news.laohu8.com/highlight/detail?id=2590377514","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590377514?lang=zh_cn&edition=full","pubTime":"2025-12-10 11:55","pubTimestamp":1765338945,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，拨康视云-B(02592)现涨超4%，截至发稿，涨4.13%，报8.58港元，成交额1182.43万港元。消息面上，拨康视云此前公告，本公司于美国加利福尼亚州注册成立的全资附属公司Cloudbreak USA排定于2025年12月10日与美国食品及药物管理局正式举行第2期临床试验后会议，该会议涉及集团临床阶段候选药物 CBT-004。此次第2期临床试验后会议是CBT-004研发进程中一个重要的里程碑，用于讨论CBT-004研发进程中潜在的第三阶段临床试验开发以及新药申请的相关要求。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1379758.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02592","BK1161","CBT","BK4090"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2589338182","title":"港股异动 | 拨康视云-B(02592)午后涨近8% 本周三附属将与美国FDA商讨CBT-004临床研发进程","url":"https://stock-news.laohu8.com/highlight/detail?id=2589338182","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589338182?lang=zh_cn&edition=full","pubTime":"2025-12-08 13:46","pubTimestamp":1765172812,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，拨康视云-B午后涨近8%，截至发稿，涨7.5%，报8.6港元，成交额765.31万港元。本集团于2023年12月开始CBT-004的第2期临床试验，并于2025年5月完成。本集团已于2025年7月完成临床试验报告并计划与美国食品及药物管理局举行第2期临床试验后会议。此次第2期临床试验后会议是CBT-004研发进程中一个重要的里程碑，用于讨论CBT-004研发进程中潜在的第三阶段临床试验开发以及新药申请的相关要求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378692.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","CBT","02592","BK4090"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2588088954","title":"港股异动 | 拨康视云-B(02592)盘中涨超4% 近一周累计涨幅逾八成 公司将加速CBT-009全球商业化潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=2588088954","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588088954?lang=zh_cn&edition=full","pubTime":"2025-12-02 10:20","pubTimestamp":1764642042,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，拨康视云-B盘中涨超4%，近一周交易日累计涨幅逾八成。消息面上，近日，拨康视云-B发布公告，公司于美国特拉华州注册成立的全资附属公司ADS Therapeutics LLC已成功在日本及欧洲成功申请专利，该等专利涉及集团核心产品之一CBT-009。公司认为，该等专利申请的成功是CBT-009研发进程中的重要里程碑，将提升CBT-009的全球覆盖范围，并促进商业化进程。有关合作及许可安排预期将提升并加速CBT-009的全球商业化潜力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1376370.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02592","BK4090","CBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2586227105","title":"港股异动 | 拨康视云-B(02592)再涨超10% 核心产品CBT-009获得日本及欧洲专利","url":"https://stock-news.laohu8.com/highlight/detail?id=2586227105","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586227105?lang=zh_cn&edition=full","pubTime":"2025-11-28 09:44","pubTimestamp":1764294298,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，拨康视云-B再涨超10%，本周累计涨幅接近70%。截至发稿，涨8.82%，报7.9港元，成交额621.89万港元。消息面上，拨康视云发布公告，美国全资附属ADS USA成功获日本专利局及欧洲专利局授出专利，涉及集团核心产品之一CBT-009。CBT-009是一种新型阿托品眼用制剂，用于治疗5至19岁儿童及青少年的青少年近视。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1374903.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","CBT","BK4090","02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2586242898","title":"拨康视云-B(02592)于日本及欧洲成功申请专利 将提升并加速CBT-009的全球商业化潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=2586242898","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586242898?lang=zh_cn&edition=full","pubTime":"2025-11-27 19:27","pubTimestamp":1764242834,"startTime":"0","endTime":"0","summary":"CBT-009作为集团的核心产品，是一种新型阿托品眼用制剂，用于治疗5至19岁儿童及青少年的青少年近视。集团亦已于2025年2月在中国开展幼年动物毒性研究，并正积极筹备CBT-009第3期临床试验的启动事宜。公司认为，该等专利申请的成功是CBT-009研发进程中的重要里程碑，将提升CBT-009的全球覆盖范围，并促进商业化进程。有关合作及许可安排预期将提升并加速CBT-009的全球商业化潜力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1374658.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","CBT","BK4090","02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2586341242","title":"卡博特旗下炭黑产品，入选进博会2025年度十大展品！","url":"https://stock-news.laohu8.com/highlight/detail?id=2586341242","media":"炭黑产业网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586341242?lang=zh_cn&edition=full","pubTime":"2025-11-24 17:15","pubTimestamp":1763975749,"startTime":"0","endTime":"0","summary":"卡博特公司11月18日对外宣布，其自主研发的先进材料LITX 95F导电炭黑成功入选中国国际进口博览会“2025年度十大展品”榜单。作为全球规模领先的贸易与经济合作博览会，进博会设立“年度十大展品”奖项，旨在表彰那些对推动可持续、高质量经济发展具有突出贡献的卓越品牌及创新成果。据悉，第八届中国国际进口博览会吸引了155个国家、地区及国际组织参与，参展企业数量超过4100家。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251124202239a70e533e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251124202239a70e533e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CBT","BK4090"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139955096","title":"卡博特公司任命罗伯特·里斯特为投资者关系与企业规划副总裁","url":"https://stock-news.laohu8.com/highlight/detail?id=1139955096","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139955096?lang=zh_cn&edition=full","pubTime":"2025-11-20 00:30","pubTimestamp":1763569853,"startTime":"0","endTime":"0","summary":"11月4日 - 卡博特公司宣布，罗伯特·里斯特被任命为投资者关系与企业规划副总裁。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4090","CBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128909337","title":"卡博特第四季度调整后每股收益1.7美元，与IBES预期持平","url":"https://stock-news.laohu8.com/highlight/detail?id=1128909337","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128909337?lang=zh_cn&edition=full","pubTime":"2025-11-20 00:30","pubTimestamp":1763569817,"startTime":"0","endTime":"0","summary":"11月03日消息 - 卡博特第四季度净收入为4300万美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CBT","BK4090"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136942380","title":"异动解读 | 卡博特股价盘前大跌5.19%，多家券商下调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1136942380","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136942380?lang=zh_cn&edition=full","pubTime":"2025-11-04 21:16","pubTimestamp":1762262199,"startTime":"0","endTime":"0","summary":"卡博特公司今日盘前股价大跌5.19%，引发市场关注。这一跌幅主要受到多家知名券商下调目标价的影响。这两家知名券商的目标价调整反映出分析师对卡博特公司未来表现的预期有所下降。卡博特公司是一家全球性的特种化学品和性能材料公司，其产品广泛应用于运输、基础设施、环境和消费等领域。券商下调目标价可能源于对全球经济增长放缓、原材料成本上升或行业竞争加剧等因素的担忧。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["CBT"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cabotcorp.com","stockEarnings":[{"period":"1week","weight":-0.0061},{"period":"1month","weight":0.069},{"period":"3month","weight":0.0681},{"period":"6month","weight":0.0507},{"period":"1year","weight":-0.0204},{"period":"ytd","weight":0.1293}],"compareEarnings":[{"period":"1week","weight":0.0137},{"period":"1month","weight":-0.0196},{"period":"3month","weight":-0.044},{"period":"6month","weight":-0.0178},{"period":"1year","weight":0.307},{"period":"ytd","weight":-0.0333}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Cabot Corporation业务初始于1882年，于1960年在特拉华州注册成立。该公司是一家全球特种化学品和性能材料公司，总部位于马萨诸塞州波士顿。公司主要产品为增强和特种碳、特种化合物、导电添加剂、碳纳米管、气相金属氧化物、喷墨着色剂和气凝胶。","yearOnYearQuotes":[{"month":1,"riseRate":0.434783,"avgChangeRate":0.012443},{"month":2,"riseRate":0.565217,"avgChangeRate":0.030841},{"month":3,"riseRate":0.608696,"avgChangeRate":0.019173},{"month":4,"riseRate":0.531915,"avgChangeRate":0.01874},{"month":5,"riseRate":0.434783,"avgChangeRate":0.001185},{"month":6,"riseRate":0.456522,"avgChangeRate":-0.000413},{"month":7,"riseRate":0.5,"avgChangeRate":0.019114},{"month":8,"riseRate":0.456522,"avgChangeRate":0.000293},{"month":9,"riseRate":0.478261,"avgChangeRate":-0.000003},{"month":10,"riseRate":0.456522,"avgChangeRate":-0.01138},{"month":11,"riseRate":0.673913,"avgChangeRate":0.018365},{"month":12,"riseRate":0.608696,"avgChangeRate":0.00955}],"exchange":"NYSE","name":"卡博特","nameEN":"Cabot"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"卡博特(CBT)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供卡博特(CBT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"卡博特,CBT,卡博特股票,卡博特股票老虎,卡博特股票老虎国际,卡博特行情,卡博特股票行情,卡博特股价,卡博特股市,卡博特股票价格,卡博特股票交易,卡博特股票购买,卡博特股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"卡博特(CBT)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供卡博特(CBT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}